PARP1 and neoplasm: Given that stabilisation of the stalled DNA replication fork leads to PARPi resistance in HRR-defective tumours, strategies that encourage collapse of this fork and so overcome replication fork protection should work to overcome this resistance, thus restoring sensitivity to PARP inhibition.